Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 10/20 | 0.60 |
| ▸ | NPFFR2 | Q9Y5X5 | 10/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11565355 | 0.99 | NPFFR1 (0.58) | NPFFR1NPFFR2OPRK1CYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL27922841 | 0.99 | NPFFR1 (0.58) | NPFFR1NPFFR2OPRK1CYP2D6CYP3A4 | |
| SCHEMBL11447239 | 0.92 | POLB (0.52) | NPFFR1NPFFR2OPRK1CYP2D6CYP3A4 | |
| SCHEMBL11448347 | 0.91 | NPFFR1 (0.51) | NPFFR1NPFFR2OPRK1CYP2D6CYP3A4 | |
| SCHEMBL13525518 | 0.91 | NPFFR1 (0.56) | NPFFR1NPFFR2OPRK1CYP2D6CYP3A4 | |
| SCHEMBL8526584 | 0.89 | NPFFR1 (0.57) | NPFFR1NPFFR2OPRK1CYP2D6CYP3A4 | |
| SCHEMBL11447661 | 0.89 | KDM4E (0.50) | NPFFR1NPFFR2OPRK1CYP2D6SIGMAR1 | |
| SCHEMBL9148987 | 0.86 | NPFFR1 (0.61) | NPFFR1NPFFR2OPRK1SIGMAR1OPRM1 | |
| SCHEMBL7953417 | 0.86 | NPFFR1 (0.57) | NPFFR1NPFFR2OPRK1CYP2D6CYP3A4 | |
| SCHEMBL8520086 | 0.86 | NPFFR1 (0.63) | NPFFR1NPFFR2OPRK1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134079-A1 | SUBSTITUTED N-(2-(AMINO)-2-OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX Discovery, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX, INC. | 2017-02-09 | — | — | US | disclosed |
| WO-2015175171-A1 | SUBSTITUTED N-(2-(AMINO)-2-OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX DISCOVERY, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015175171-A1 | SUBSTITUTED N-(2-(AMINO)-2-OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX DISCOVERY, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| EP-2455377-B1 | Synthesis of fentanyl analogs | HAMELN RDS GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2455377-B1 | Synthesis of fentanyl analogs | HAMELN RDS GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2455377-A1 | Synthesis of fentanyl analogs | hameln rds gmbh (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2455377-A1 | Synthesis of fentanyl analogs | hameln rds gmbh (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-4208418-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-06-17 | — | — | US | disclosed |
| US-4198411-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-15 | — | — | US | disclosed |
| US-4197303-A | ANTIARRHYTHMIA AGENTS, ALKOXYCARBONYL ON 4-POSITION OF PIPERIDINE | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4197304-A | ANTIARRHYTHMIA AGENTS, N-PYRIDINYL-N-(4-ALKYLPIPERIDINYL)THIENYLACETAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-08 | — | — | US | disclosed |
| US-4196210-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-04-01 | — | — | US | disclosed |
| US-4179569-A | ANALGESIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
| US-4157393-A | ANTIARRHYTHMIA AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-06-05 | — | — | US | disclosed |
| US-4151286-A | ANTIARRHYTHMIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-04-24 | — | — | US | disclosed |
| US-4126689-A | ANTIARRHYTHMIA | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
| US-3998834-A | ANALGESICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | ENPP2, LPAR2, LPCAT3 | NPFFR1 2152/4885NPFFR2 1207/4885OPRK1 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.